The Pharma 5: Washington knocks out wobbly D2C exception to worthy Learned Intermediary

This month, Jackie Karama, an associate in Los Angeles whose practice focuses on pharma disputes, discusses:

  • Securities – clinical trials
  • Consumer sales – standing
  • FDA - NDA regulation
  • Orphan Drug Act – exclusivity
  • Learned Intermediary – D2C
card-grid-item, aem-sourced
The Pharma 5 video series
C35F98C0-15A6-4C0C-B889-740DE026B58E